The purpose of this study is to determine whether recombinant human thrombopoietin(rhTPO) can rapidly increase the platelet counts, shorten the time of the platelet returned to normal, reduce platelet transfusion and bleeding events, decrease the length of ICU stay, and eventually reduce the 28-day mortality in septic shock patients with thrombocytopenia.